Tigilanol tiglate

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.

Get In Touch With QBiotics to Discuss Its Positive Solid Tumor Efficacy Data and Phase II Clinical Program at Bio 2022

Retrieved on: 
Wednesday, June 1, 2022
Melanoma, Bio, Phase II, Patient, Tigilanol tiglate, Head, Biotechnology, Death, Wound healing, Neoplasm, Telescopic sight, Medical imaging, Vaccine

Brisbane, Australia--(Newsfile Corp. - June 1, 2022) - Australian life science company, QBiotics will showcase positive efficacy data from its completed phase I trial of lead cancer molecule, tigilanol tiglate, and its Phase II clinical program at Bio 2022, the world's largest gathering of biotechnology and pharma leaders.

Key Points: 
  • Brisbane, Australia--(Newsfile Corp. - June 1, 2022) - Australian life science company, QBiotics will showcase positive efficacy data from its completed phase I trial of lead cancer molecule, tigilanol tiglate, and its Phase II clinical program at Bio 2022, the world's largest gathering of biotechnology and pharma leaders.
  • Phase II clinical programs in patients with head and neck squamous cell carcinoma, melanoma (and soon) soft tissue sarcoma.
  • Success in the veterinary programs validates QBiotics' technology and de-risks human development, while generating early, non-dilutive revenues.
  • More information: https://qbiotics.com
    Tigilanol tiglate is a novel, small molecule in development as an intratumoral injection treatment for solid tumors.

New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®

Retrieved on: 
Tuesday, July 6, 2021
Health sciences, Chemical compounds, Chemistry, Alcohols, Cyclopropanes, Epoxides, Ketones, Tigilanol tiglate, Pharmaceutical industry, Cancer

This approval represents Australia's first pharmaceutical treatment available for all grades of canine non-metastatic MCT.

Key Points: 
  • This approval represents Australia's first pharmaceutical treatment available for all grades of canine non-metastatic MCT.
  • QBiotics' CEO and Managing Director, Dr Victoria Gordon said "APVMA approval of STELFONTAmarks an important milestone for QBiotics.
  • As an Australian company with a strong heritage in discovery, research and development, we are proud that our lead molecule will now be available to treat cancer in Australian dogs."
  • In this study,a single injection of STELFONTA induced a 75% Complete Response (where the tumour is completely destroyed), compared to untreated control dogs (p=0.001).

QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours

Retrieved on: 
Wednesday, November 18, 2020
Chemical compounds, Organic compounds, Chemistry, Alcohols, Cyclopropanes, Diterpenes, Epoxides, Ketones, Tigilanol tiglate, Mastocytoma

The efficacy and durability of response data in dogs with mast cell tumours are very promising.

Key Points: 
  • The efficacy and durability of response data in dogs with mast cell tumours are very promising.
  • While surgery will remain the mainstay, I do think STELFONTA will reshape how we approach local mast cell tumour control in many ways."
  • Dr Victoria Gordon, CEO and Managing Director of QBiotics, said, "FDA approval is a pivotal achievement for both STELFONTA and QBiotics.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoural treatment of canine mast cell tumours with tigilanol tiglate (EBC-46).

QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours

Retrieved on: 
Wednesday, November 18, 2020
Chemical compounds, Organic compounds, Chemistry, Alcohols, Cyclopropanes, Diterpenes, Epoxides, Ketones, Tigilanol tiglate, Mastocytoma

The efficacy and durability of response data in dogs with mast cell tumours are very promising.

Key Points: 
  • The efficacy and durability of response data in dogs with mast cell tumours are very promising.
  • While surgery will remain the mainstay, I do think STELFONTA will reshape how we approach local mast cell tumour control in many ways."
  • Dr Victoria Gordon, CEO and Managing Director of QBiotics, said, "FDA approval is a pivotal achievement for both STELFONTA and QBiotics.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoural treatment of canine mast cell tumours with tigilanol tiglate (EBC-46).